CURRICULUM VITAE
Ryoichi Fujiwara

Education

2000-2004 Kitasato University, Tokyo, Japan. School of Pharmacy (**Registered Pharmacist**)

2004-2006 Kanazawa University, Kanazawa, Japan. Graduate School of Natural Science & Technology, Master in Pharmaceutical Sciences (**MS**)

2006-2008 Kanazawa University, Kanazawa, Japan. Graduate School of Natural Science & Technology, Doctorate in Pharmaceutical Sciences (**Ph.D.**)

Employment

2008- 2012 University of California, San Diego, Department of Pharmacology, **Postdoctoral Researcher** in Dr. Robert H. Tukey's laboratory

2012-2018 Kitasato University, School of Pharmacy, Japan, **Assistant Professor**

2017 Tübingen University, Tübingen, Germany, **Guest Professor**

2018 University of Arkansas for Medical Sciences, **Research Associate**

2019-2021 University of Arkansas for Medical Sciences, **Assistant Professor**

2022-2025 Northeast Ohio Medical University (NEOMED), **Assistant Professor**

2023-2024 **Interim Director of Pipeline Programs**, NEOMED

2025-Present **Assistant Dean of Student Success**, The University of Texas at Tyler (UT Tyler) Ben and Maytee Fisch College of Pharmacy

2025-Present **Assistant Dean of Student Success**, The University of Texas at Tyler (UT Tyler) Ben and Maytee Fisch College of Pharmacy

Awards

2008 **Best Poster Award**. The 12th International Workshop on Glucuronidation and UGT enzymes. Québec, Canada.

2010 **Editors' Award for the Most Excellent Article in *Drug Metab Pharmacokinet***

2014 **Best Original Paper Award by Nestlé Nutrition Council, Japan (NNCJ).**

2016 **Young Investigator's Award**. The Japanese Society for the Study of Xenobiotics.

2019 **Top Reviewer Award.** *The Journal of Pharmaceutical Sciences*

2021 **Rho Chi Teacher of the Year. UAMS, College of Pharmacy**

2023 **P1 Teacher of the Year. NEOMED, College of Pharmacy**

2025 **P1 Teacher of the Year. NEOMED, College of Pharmacy**

CURRICULUM VITAE
Ryoichi Fujiwara

Lectures and courses

2012-2018 in Kitasato University, Japan

- ***Pharmaceutics*** as a course director and a main instructor
- ***Pharmacokinetics*** as a course director and a main instructor
- ***Supplements*** as a co-instructor
- ***Eastern medicine*** as a co-instructor
- ***Pharmacology*** as a co-instructor
- ***Pharmacogenomics*** as a co-instructor

2019-2021 at the University of Arkansas for Medical Sciences

- ***Pharmaceutics I*** (PHSC 7104, 3 credit hours) as a course director and a main instructor
- ***Pharmaceutics II*** (PHSC 7105, 4 credit hours) as a course director and a main instructor
- ***Carrier Orientation*** (PHPR 7103, 2 credit hours) as a co-instructor
- ***Clinical Pharmacokinetics*** (PHPR 7205, 2 credit hours) as a co-instructor
- ***Pharmaceutics*** *(*PSGP 5102, 3 credit hours) as a course director and a main instructor

2022-2025 at NEOMED

- ***Pharmaceutical Calculations*** (2.5 credit hours) as a course director and a main instructor
- ***Pharmaceutics*** (PCEU-72203, 3 credit hours) as a main instructor
- ***Systems Biology Omics Technologies*** (PELE-70029, 1 credit hour) as a co-instructor
- ***Immunology and Biotechnology*** (IMMU-71302, 3 credit hours) as a co-instructor
- ***Pharmacodynamics and Pharmacokinetics (PHDD 71305,*** 4 credit hours) as a main instructor

2025-present at UT Tyler

- ***Basic Pharmacokinetics*** (3 credit hours) as a course coordinator and a main instructor

Committee services

- **Awards and Financial Aid Committee** at UAMS, College of Pharmacy (2020-2021)
- **Student Research Committee** at UAMS, College of Pharmacy (2020-2021)
- **Awards committee** at AACP, Pharmaceutics section (2020-2021)
- **Abstract Review Committee** for 2021 Annual meeting at AACP (2020-2022)
- **Curriculum Committee** at NEOMED, College of Pharmacy (2022-2025)
- **Outcomes Assessment Committee** at NEOMED, College of Pharmacy (2022-2025)

CURRICULUM VITAE
Ryoichi Fujiwara

Publication list

1. Fujiwara R, Nakajima M, Yamanaka H, Nakamura A, Katoh M, Ikushiro S, and Yokoi T. Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. ***Drug Metab. Dispos***. 35: 747-757, 2007.

2. Nakajima M, Yamanaka H, Fujiwara R, Katoh M, and Yokoi T. Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15:effects of UGT-UGT interactions. ***Drug Metab. Dispos***. 35: 1679-1686, 2007.

3. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T. Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. ***Drug Metab. Dispos***. 35: 1781-1787, 2007.

4. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T. Product inhibition of UDP-glucuronosyltransferase (UGT) enzymes by UDP obfuscates the inhibitory effects of UGT substrates. ***Drug Metab. Dispos***. 36: 361-367, 2008.

5. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, and Yokoi T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. ***Drug Metab. Dispos***. 36: 1461-1464, 2008.

6. Fujiwara R, Nakajima M, Yamanaka H, and Yokoi T. Key amino acid residues responsible for the differences in substrate specificity of human UDP-glucuronosyltransferase (UGT) 1A9 and UGT1A8. ***Drug Metab. Dispos***. 37: 41-46, 2009.

7. Fujiwara R, Nakajima M, Yamamoto T, Nagao H, and Yokoi T. In silico and in vitro approaches to elucidate the thermal stability of human UDP-glucuronosyltransferase (UGT) 1A9. ***Drug Metab. Pharmacokinet***. 24: 235-244, 2009.

8. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers.***Drug Metab. Dispos***. 37: 1759-1768, 2009.

9. Fujiwara R, Nakajima M, Oda S, Yamanaka H, Ikushiro S, Sakaki T, and Yokoi T. Interactions between human UDPglucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. ***J Pharm Sci***. 99: 442-452, 2010.

10. Fujiwara R, Nguyen N, Chen S, Tukey RH. 2010. Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the *UDP-Glucuronosyltransferase 1 (UGT1)* locus. ***Proc Natl Acad Sci USA*** 107**:** 5024-5029, 2010.

11. Nakajima M, Koga T, Sakai H, Yamanaka H, Fujiwara R, and Yokoi T. N-Glycosylation plays a role in protein folding of human UGT1A9. ***Biochem Pharmacol***. 79: 1165-1172, 2010.

12. Koga T, Fujiwara R, Nakajima M, and Yokoi T. Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. ***Drug Metab Dispos***. 39: 54-60, 2010.

13. Abe Y, Fujiwara R, Oda S, Yokoi T, and Nakajima M. Interpretation for the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. ***Drug Metab Pharmacokinet***. 26:256-65, 2011.

14. Fujiwara R, Chen S, Tukey RH. Suppression of UGT1A1 in Intestine of Neonatal Mice, via Inactivation of NF-κB, Leads to Hyperbilirubinemia. ***Gastroenterology.*** 142: 109-118, 2012.

15. Sumida K, Kawana M, Kouno E, Itoh M, Takano S, Narawa T, Tukey RH, and Fujiwara R. Importance of UDPglucuronosyltransferase 1A1 Expression in Skin and its Induction by Ultraviolet B in Neonatal Hyperbilirubinemia. ***Mol Pharmacol***. 84:679-686, 2013.

16. Takenaka S, Itoh T, and Fujiwara R. Expression pattern of human ATP-binding cassette transporters in skin. ***Pharmacology Research & Perspectives***. 1:e00005, 2013.

17. Kutsuno Y, Itoh T, and Fujiwara R. Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes. ***Pharmacology Research & Perspectives.*** 1:e00002, 2013.

18. Sakamoto M, Itoh T, and Fujiwara R. Prediction of in vivo carbamazepine 10,11-epoxidation from in vitro metabolic studies with human liver microsomes: Importance of its sigmoidal kinetics. ***Biol Pharm Bull***. 36:1959-1963, 2013.

19. Shibuya A, Itoh T, Tukey RH, and Fujiwara R. Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. ***Sci Rep***. 3:2903, 2013.

20. Fujiwara R and Itoh T. Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. ***Drug Metab Pharmacokinet.*** 29:259-265, 2014.

21. Fujiwara R and Itoh T. Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. ***Pharmacology Research & Perspectives.*** 2:e00053, 2014.

22. Kutsuno Y, Itoh T, Tukey RH, and Fujiwara R. Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice. ***Drug Metab Dispos***. 42:1146-52, 2014.

23. Fujiwara R, Takenaka S, Hashimoto M, Narawa T, and Itoh T. Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders. ***Sci Rep***. 4:5251, 2014.

24. Asakura M, Nakano M, Hayashida K, Fujii H, Nakajima M, Atsuda K, Itoh T, and Fujiwara R. Human nitrilase-like protein does not catalyze the hydrolysis of vildagliptin. ***Drug Metab Pharmacokinet***. 29:463-469, 2014.

25. Aoshima N, Fujie Y, Itoh T, Tukey RH, and Fujiwara R. Glucose induces intestinal human UDPglucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia. ***Sci Rep***. 4:6343, 2014.

26. Asakura M, Fujii H, Atsuda K, Itoh T, and Fujiwara R. Dipeptidyl Peptidase-4 Greatly Contributes to the Hydrolysis of Vildagliptin in Human Liver. ***Drug Metab Dispos***. 2015, 43:477-484, 2015.

27. Li G, Nakagome I, Hirono S, Itoh T, and Fujiwara R. Inhibition of adenosine deaminase (ADA)-mediated metabolism of cordycepin by natural substances. ***Pharmacology Research & Perspectives.*** 3:e00121, 2015.

28. Fujiwara R, Sumida K, Kutsuno Y, Sakamoto M, and Itoh T. UDP-Glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin. ***Drug Metab Pharmacokinet***. 30:82-88, 2015.

29. Oda S, Fujiwara R, Kutsuno Y, Fukami T, Itoh T, Yokoi T, and Nakajima M. Targeted screen for human UDPglucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. ***Drug Metab Dispos***. 43:812-8, 2015.

30. Kutsuno Y, Hirashima R, Sakamoto M, Ushikubo H, Michimae H, Itoh T, Tukey RH, and Fujiwara R. Expression of UDP-glucuronosyltransferase 1 (UGT1) and glucuronidation activity toward endogenous substances in humanized UGT1 mouse brain. ***Drug Metab Dispos***. 43:1071-6, 2015.

31. Sakamoto M, Itoh T, Tukey RH, and Fujiwara R. Nicotine regulates the expression of UDP-glucuronosyltransferase (UGT) in humanized UGT1 mouse brain. ***Drug Metab Pharmacokinet***. 30:269-75, 2015.

32. Takagi M, Sakamoto M, Itoh T, and Fujiwara R. Underlying mechanism of drug–drug interaction between pioglitazone and gemfibrozil: Gemfibrozil acyl-glucuronide is a mechanism-based inhibitor of CYP2C8. ***Drug Metab Pharmacokinet***. 30:288-94, 2015.

33. Mitsugi R, Itoh T, and Fujiwara R. Expression of human DNAJ (heat shock protein-40) B3 in humanized UDPglucuronosyltransferase 1 mice. ***Int J Mol Sci***. 16:14997-15008, 2015.

34. Fujiwara R, Maruo Y, Chen S, and Tukey RH. Role of extrahepatic UDP-glucuronosyltransferase 1A1: advances in understanding breast milk-induced neonatal hyperbilirubinemia. ***Toxicol Appl Pharmacol***. 289:124-32, 2015.

35. Liu M, Chen S, Yueh MF, Fujiwara R, Konopnicki C, Hao H, and Tukey RH. Cadmium and arsenic override NF-κB developmental regulation of the intestinal UGT1A1 gene and control of hyperbilirubinemia. ***Biochem Pharmacol***. 110-111:37-46, 2016.

36. Fujiwara R, Yokoi T, Nakajima M.Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases. ***Front Pharmacol***. 7:388, 2016.

37. Yamashita Y, Asakura M, Mitsugi R, Fujii H, Nagai K, Atsuda K, Itoh T, and Fujiwara R. MicroRNA expression in the vildagliptin-treated two- and three-dimensional HepG2 cells. ***Drug Metab Pharmacokinet.*** 31:201-209, 2016.

38. Hirashima R, Michimae H, Takemoto H, Sasaki A, Kobayashi Y, Itoh T, Tukey RH, and Fujiwara R. Induction of the UDP-Glucuronosyltransferase 1A1 during the Perinatal Period Can Cause Neurodevelopmental Toxicity. ***Mol Pharmacol***. 90:265-74, 2016.

39. Mitsugi R, Itoh T, and Fujiwara R. MicroRNA-877-5p is involved in the trovafloxacin-induced liver injury. ***Toxicol Lett***. 263:34-43, 2016.

40. Mitsugi R, Sumida K, Fujie Y, Tukey RH, Itoh T, and Fujiwara R. Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide. ***Biol Pharm Bull***. 39:1604-1610, 2016.

41. Asakura M, Karaki F, Fujii H, Atsuda K, Itoh T, and Fujiwara R. Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cells. ***Sci Rep***. 6:35633, 2016.

42. Asakura M, Fukami T, Nakajima M, Fujii H, Atsuda K, Itoh T, and Fujiwara R. Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo. ***Drug Metab Dispos***. 45:237-245, 2017.

43. Hirashima R, Itoh T, Tukey RH, and Fujiwara R. Prediction of drug-induced liver injury using keratinocytes. ***J Appl Toxicol***. 37:863-872, 2017.

44. Yoda E, Paszek M, Konopnicki C, Fujiwara R, Chen S, and Tukey RH. Isothiocyanates induce UGT1A1 in humanized UGT1 mice in a CAR dependent fashion that is highly dependent upon oxidative stress. ***Sci Rep***. 7:46489, 2017.

43. Koyama M, Shirahata T, Hirashima R, Kobayashi Y, Itoh T, and Fujiwara R. Inhibition of UDP-glucuronosyltransferase (UGT)-mediated glycyrrhetinic acid 3-O-glucuronidation by polyphenols and triterpenoids. ***Drug Metab Pharmacokinet***. 32:218-223, 2017.

44. Fujiwara R, Mitsugi R, Uemura A, Itoh T, and Tukey RH. Severe neonatal hyperbilirubinemia in Crigler-Najjar syndrome model mice can be reversed with zinc protoporphyrin. ***Hepatology Communications***. 1:792-802, 2017.

45. Uchida T, Wakasugi M, Kitamura T, Yamamoto T, Asakura M, Fujiwara R, Itoh T, Fujii H, Hirono S. Exploration of DPP-IV inhibitors with a novel scaffold by multistep in silico screening. ***J Mol Graph Model***. 79:254-263, 2018.

46. Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. ***Biochem Biophys Res Commun***. 498:597-602, 2018.

47. Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A and Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC. ***Front Pharmacol***. 9:1084, 2018.

48. Fujiwara R, Yoda E, Tukey RH. Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans. ***Drug Metab Pharmacokinet***. 33:9-16, 2018.

49. Fujiwara R, Haag M, Schäffeler E, Nies AT, Zanger UM, and Schwab M. Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia. Invited from ***Hepatology***. 67:1609-1619, 2018.

50. Fujiwara R. Exposure to sub-parts per million levels of vinyl chloride can increase the risk of developing liver injury. Fujiwara R. ***Hepatol Commun***. 2:227-229, 2018.

51. Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE. Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice. ***J Pharmacol Exp Ther***. 368:146-156, 2019.

52. Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic Analysis of Glucuronidation of Synthetic Cannabinoid 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). ***Xenobiotica***. 49:1388-1395, 2019.

53. Kazuki Y, Kobayashi K, Hirabayashi M, Abe S, Kajitani N, Kazuki K, Takehara S, Takiguchi M, Satoh D, Kuze J, Sakuma T, Kaneko T, Mashimo T, Osamura M, Hashimoto M, Wakatsuki R, Hirashima R, Fujiwara R, Deguchi T, Kurihara A, Tsukazaki Y, Senda N, Yamamoto T, Scheer

N, Oshimura M. Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism. ***Proc Natl Acad Sci USA***. 116:3072-3081, 2019.

54. Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). ***Pharmacol Res Perspect***. 2020 Feb;8(1):e00561.

55. Pinson A, Yarbrough AL, Bush JM, Cabanlong CV, Shoeib A, Jackson BK, Fukuda S, Gogoi J, Fantegrossi WE, McCain K, Prather PL, Fujiwara R, Radominska-Pandya A. Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity. ***Pharmacol Biochem Behav***. 195: 172949, 2020.

56. Fujiwara R. Balancing act. ***Science***. 371: 750, 2021.

57. Moon SH, Kaufmann Y, Fujiwara R, Huang E. Enzymatically-crosslinked gelatin hydrogels containing paenipeptin and clarithromycin against carbapenem-resistant pathogen in murine skin wound infection. ***BMC Microbiol***. 21:326, 2021.

58. Jones S, Al-Doori F, Fujiwara R. Prediction of milk plasma ratio for amphoteric substances. ***Pharmacol Res Perspect***. 11:e01042, 2023.

59. Fujiwara R, Journey M, Al-Doori F, Bell P, Judge B, Miracle K, Ito K, Jones S. Potential neonatal toxicity of new psychoactive substances. ***Pharmacol Ther.*** 248:108468, 2023

60. Tran N, Fantegrossi WE, McCain KR, Wang X, Fujiwara R. Identification of Cytochrome P450 Enzymes Responsible for Oxidative Metabolism of Synthetic Cannabinoid (1-Hexyl-1H-Indol-3-yl)-1-naphthalenyl-methanone (JWH-019). ***Catalysts***. 13:1008. 2023

61. Fujiwara R. Pharmacy School and Pharm.D. Program in the United States of America. ***Yakugaku Zasshi***. 143:793-797, 2023.

62. McMillen A, Brosch H, Zakhary K, Juzkiw S, Fredrickson L, Tromp KM, Fujiwara R. Retrospective study assessing student utilization of optional practice questions on pharmacy calculations final examination performance. ***Curr Pharm Teach Learn***. 16:102203, 2024.

63. Leskiw E, Whaley A, Hopwood P, Houston T, Murib N, Al-Falih D, Fujiwara R. Validating Disease Associations of Drug-Metabolizing Enzymes through Genome-Wide Association Study Data Analysis. ***Genes (Basel).*** 15:1326, 2024.

PubMed link: https://pubmed.ncbi.nlm.nih.gov/?term=fujiwara%2Cryoichi

Book Chapters

1. Fujiwara R. Chapter 90: Fetal and Neonatal Bilirubin Metabolism. ***Fetal and Neonatal Physiology, 6th edition***. ISBN-13: 9780323712859, page 915-918, 2021

2. Fujiwara R. Chapter 89: Fetal and Neonatal Bilirubin Metabolism. ***Fetal and Neonatal Physiology*, 7th edition.** (Submitted in Dec 2024 Dec)

3. Cober P., Fredrickson L, and Fujiwara R. Chapter 11 Pharmacy Calculations. ***ASHP Manual for Pharmacy Technicians***. (Submitted in Jan 2025)

Invited Talks

1. Role of bilirubin metabolism in neonatal hyperbilirubinemia, Seminar at Kitasato University, Tokyo, Japan (Invited by Professor Tomoo Itoh), September 2010.

2. Role of bilirubin metabolism in neonatal hyperbilirubinemia, Seminar at Shimane University, Shimane, Japan (Invited by Professor Atsushi Horiguchi), September 2010.

3. Role of Gastrointestinal UDP-Glucuronosyltransferase (UGT) 1A1 in Bilirubin Metabolism. Pharmacology Research Discussion, San Diego, February 2011.

4. The importance of gastrointestinal UDP-glucuronosyltransferase 1A1 in bilirubin metabolism in neonatal hyperbilirubinemia. Symposium at the 27th JSSX Annual Meeting, November 2012.

5. Importance of extrahepatic UDP-glucuronosyltransferases in drug metabolism and toxicity. Shirokane Symposium at Kitasato University, Tokyo, Japan, February 2014.

6. Glucuronidation of drugs in humanized UDP-glucuronosyltransferase (UGT) 1 mice. Symposium at the 134th Annual Meeting of the Pharmaceutical Society of Japan, March 2014.

7. Acyl-glucuronidation and its toxicity. Symposium at the 41st JSOT Annual Meeting, July 2014.

8. Role of gastrointestinal UDP-glucuronosyltransferase (UGT) 1A1 in neonatal hyperbilirubinemia. Invited lecture (PSET Seminar) at University of Iowa, School of Pharmacy, Iowa, November 2014.

9. Importance of extrahepatic UDP-glucuronosyltransferases in drug metabolism and toxicity. Seminar at Tottori University, Torrori, Japan (Invited by Professor Kazuki), February 2015.

10. Importance of extrahepatic UDP-glucuronosyltransferase 1A1 in bilirubin metabolism. Annual Meeting of the German Pharmaceutical Society (DPhG), Dusseldorf, Germany, September 2015.

11. Induction of UDP-glucuronosyltransferase 1A1 can cause decreased thyroxin levels and neurotoxicity. The 30th JSSX Annual Meeting, Tokyo, November 2015.

12. The effect of the UDP-glucuronosyltransferase 1A1 induction on the neurodevelopment during the perinatal period. Symposium at the 136th Annual Meeting of the Pharmaceutical Society of Japan, March 2016.

13. Induction of UDP-glucuronosyltransferase 1A1 can decrease serum T4 levels and increase a risk of developing neurotoxicity: Study in wild-type mice and humanized UGT1 mice. INTERNATIONAL WORKSHOP ON CONJUGATION 2016, Canada, June 2016.

14. Induction of UDP-glucuronosyltransferase 1A1 during the perinatal period can reduce blood thyroxine levels, causing neurodevelopmental toxicity. 2016 FIP Congress, Argentina, August 2016.

15. Study on hepatic and extrahepatic UDP-glucuronosyltransferase. The 31st JSSX Annual Meeting, Tokyo, October 2016.

16. Bilirubin Metabolism and its impact. Invited Seminar at Soka University, Tokyo, Japan (Invited by Professor Yuri Aoyama), December 2016.

17. Role of UDP-glucuronosyltransferase 1A1 in neonatal hyperbilirubinemia. Invited Lecture at Showa University, Tokyo, Japan (Invited by Professor Shuntaro Hara), December 2016.

18. Successful treatment of Crigler-Najjar syndrome model mice with zinc protoporphyrin: Understanding the beneficial effects of hyperbilirubinemia. Invited seminar at The International Centre for Genetic Engineering and Biotechnology, Italy, October 2017.

19. Role of extrahepatic UDP-glucuronosyltransferase (UGT) 1A1 in neonatal hyperbilirubinemia. Invited seminar at UAMS Biochemistry & Molecular Biology Department, January 2018.

20. Skin-based prediction of Drug-induced liver injury in individuals. Invited seminar at UAMS Pharmacology & Toxicology Department, March 2018.

21. Multifunctional protein UDP-glucuronosyltransferase in biochemistry, cancer, and translational research at UAMS Biochemistry & Molecular Biology Department, April 2018.

22. Role of extrahepatic UDP-glucuronosyltransferase (UGT) 1A1 in neonatal hyperbilirubinemia: Potential importance of jaundice. Invited seminar at UAMS College of Pharmacy, August 2018.

23. Role of glucuronidation in drug metabolism and toxicity. Invited seminar at Short Course 2: Non-P450 Enzymes in ADMET for Drug Discovery and Development at the ISSX Annual Meeting, July 2019.

24. Importance of Intestinal UDP-Glucuronosyltransferase in Neonatal Bilirubin Metabolism. Invited seminar at South Dakota State University, February 2022.

25. Understanding neonatal hyperbilirubinemia and kernicterus. Invited seminar at Northeast Ohio Medical University, College of Pharmacy, Department of Pharmaceutical Sciences, February 2022.

26. Pharm.D. program in Japan and the U.S.A. Invited symposium, Science Council of Japan, Tokyo (virtual), November 2022.

27. Pharm.D. Program in the USA. Invited FD seminar at Hokuriku University, Japan, March 2025

28. Pharm.D. Program in the USA. Invited FD seminar at Tohoku Medical and Pharmaceutical University, Japan, March 2025

Grants

- Grant-in-Aid for Research Activity Start-up (Japan), 2012-2013
- Kitasato University Research Grant for Young Researchers (Japan), 2012-2016
- Uehara Memorial Foundation (Japan), 2013
- Mochida Memorial Foundation for Medical and Pharmaceutical Research (Japan), 2013
- Grant-in-Aid for Young Scientists (Japan), 2014-2015
- NIH/NIDA R01-DA039143 (Co-funded; PI: Dr. Paul Prather at UAMS), 2016-2021
- NIGMS P20 GM109005 (Co-funded; PI: Dr. Marjan Boerma at UAMS), 2020-2021

Editorial Experience

- **Associate Editor**, *Pharmacology Research & Perspectives*
- **Editorial Board Member**, *Currents in Pharmacy Teaching and Learning*
- **Editorial Board Member**, *Drug Metabolism Reviews*
- **Editorial Advisory Board Member,** *Journal of Pharmaceutical Sciences*
- Reviewer, *Biological and Pharmaceutical Bulletin*
- Reviewer, *Biopharmaceutics & Drug Disposition*
- Reviewer, *British Journal of Pharmacology*
- Reviewer, *Canadian Journal of Gastroenterology and Hepatology*
- Reviewer, *Cancer Chemotherapy and Pharmacology*
- Reviewer, *Cell Biology and Toxicology*
- Reviewer, *Chemico-Biological Interactions*
- Reviewer, *Chemosphere*
- Reviewer, *Critical Reviews in Biotechnology*
- Reviewer, *Current Drug Metabolism*
- Reviewer, *Current Pediatric Reviews*
- Reviewer, *Diabetes, Metabolic Syndrome and Obesity*
- Reviewer, *Drug Metabolism Letters*
- Reviewer, *Drug Metab. Pharmacokinet*
- Reviewer, *Environmental Toxicology and Pharmacology*
- Reviewer, *Expert Opinion on Drug Metabolism & Toxicology*
- Reviewer, *Food and Chemical Toxicology*
- Reviewer, *Frontiers in Pharmacology*
- Reviewer, *Frontiers in Genetics*
- Reviewer, *Hepatology Communications*
- Reviewer, *International Journal of Molecular Sciences*
- Reviewer, *Journal of Agricultural and Food Chemistry*
- Reviewer, *Journal of Applied Toxicology*
- Reviewer, *Journal of Biological Chemistry*
- Reviewer, *Journal of Biomedical Science*
- Reviewer, *Journal of Endocrinology and Diabetes Research*
- Reviewer, *Journal of Functional Foods*
- Reviewer, *Journal of Gastrointestinal and Liver Diseases*
- Reviewer, *Journal of Neuroinflammation*
- Reviewer, *The Journal of Steroid Biochemistry and Molecular Biology*
- Reviewer, *Laboratory Investigation*
- Reviewer, *Metabolic Brain Disease*
- Reviewer, *Molecular Pharmaceutics*
- Reviewer, *Molecular Pharmacology*
- Reviewer, *Molecules*
- Reviewer, *National Research, Development and Innovation Office (Hungary)*
- Reviewer, *Neonatology*
- Reviewer, *Next Generation Sequencing & Applications*
- Reviewer, *Nutrition and Metabolism*
- Reviewer, *Pediatric Research*
- Reviewer, *Pediatrics*
- Reviewer, *Pharmacogenomics and Personalized Medicine*

- Reviewer, *Plos One*
- Reviewer, *Saudi Pharmaceutical Journal*
- Reviewer, *Toxicological Sciences*
- Reviewer, *Xenobiotics*

Verified review history can be seen here:
https://publons.com/researcher/1511452/ryoichi-fujiwara/